This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (51)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Xu et al¹ previously reported that lysophosphatidic acid (LPA) levels are increased in the plasma of patients with ovarian cancer, and they proposed that LPA may be a useful early marker of ovarian cancer. Other studies have also reported that LPA levels are increased in malignant effusions in patients with cancer,^2-3 particularly of the ovaries.⁴ To assess the utility of LPA as a marker of ovarian cancer, we measured the amount of LPA in plasma from patients with ovarian cancer and from healthy control subjects, as well as LPA levels in fluid from malignant effusions.

Methods

Using liquid chromotography/mass spectroscopy,⁵ we measured plasma concentrations of 5 individual LPA acyl species (LPA 16:0, 18:2, 18:1, 18:0, and 20:4, which comprise more than 90% of total plasma LPA) in 32 patients with ovarian cancer and 32 healthy control subjects (mean [SD] age, 53 [13] and 42 [12] years, respectively). We . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Plasma Lysophosphatidylcholine Levels: Potential Biomarkers for Colorectal Cancer
Zhao et al.
JCO 2007;25:2696-2701.
ABSTRACT | FULL TEXT  

Of Spiders and Crabs: The Emergence of Lysophospholipids and Their Metabolic Pathways as Targets for Therapy in Cancer.
Murph et al.
Clin. Cancer Res. 2006;12:6598-6602.
ABSTRACT | FULL TEXT  

Hypoxia Enhances Lysophosphatidic Acid Responsiveness in Ovarian Cancer Cells and Lysophosphatidic Acid Induces Ovarian Tumor Metastasis In vivo
Kim et al.
Cancer Res. 2006;66:7983-7990.
ABSTRACT | FULL TEXT  

Hydrolysis of Phosphatidylserine-exposing Red Blood Cells by Secretory Phospholipase A2 Generates Lysophosphatidic Acid and Results in Vascular Dysfunction
Neidlinger et al.
J. Biol. Chem. 2006;281:775-781.
ABSTRACT | FULL TEXT  

Identification of Residues Responsible for Ligand Recognition and Regioisomeric Selectivity of Lysophosphatidic Acid Receptors Expressed in Mammalian Cells
Fujiwara et al.
J. Biol. Chem. 2005;280:35038-35050.
ABSTRACT | FULL TEXT  

Inhibition of Autotaxin by Lysophosphatidic Acid and Sphingosine 1-Phosphate
van Meeteren et al.
J. Biol. Chem. 2005;280:21155-21161.
ABSTRACT | FULL TEXT  

Alendronate Inhibits Intraperitoneal Dissemination in In vivo Ovarian Cancer Model
Hashimoto et al.
Cancer Res. 2005;65:540-545.
ABSTRACT | FULL TEXT  

Lysophospholipids Are Potential Biomarkers of Ovarian Cancer
Sutphen et al.
Cancer Epidemiol. Biomarkers Prev. 2004;13:1185-1191.
ABSTRACT | FULL TEXT  

Mechanisms for Lysophosphatidic Acid-induced Cytokine Production in Ovarian Cancer Cells
Fang et al.
J. Biol. Chem. 2004;279:9653-9661.
ABSTRACT | FULL TEXT  

Lysophosphatidic Acid Signals through Mitogen-Activated Protein Kinase-Extracellular Signal Regulated Kinase in Ovarian Theca Cells Expressing the LPA1/edg2-Receptor: Involvement of a Nonclassical Pathway?
Budnik et al.
Mol. Endocrinol. 2003;17:1593-1606.
ABSTRACT | FULL TEXT  

From the Cover: Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist
McIntyre et al.
Proc. Natl. Acad. Sci. USA 2003;100:131-136.
ABSTRACT | FULL TEXT